Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / Private Equity Is Buying Up Home Health Agencies
Transcript
- Lucas: So in 2025, private equity firms completed 178 acquisitions of home health agencies across the United States. That's a 59 percent increase from the 112 deals they did in 2020, according to data from MergerMarket. Luna: That's a big jump. What's driving private equity to focus on home health all of a sudden? Lucas: It's not exactly sudden, but the pace has definitely accelerated. The core thesis is demographic inevitability. The oldest baby boomers are now in their early eighties, and the Medicare population is growing by roughly ten thousand people per day. Home health is cheaper than nursing homes, patients prefer it, and Medicare pays for it through a prospective payment system that's actually fairly predictable. Luna: So steady government reimbursement, growing demand — that sounds like a recipe for stable cash flows. What are the margins like? Lucas: Good margins if you manage labor costs well. A well-run agency can see EBITDA margins in the 15 to 20 percent range. But labor is the squeeze. Home health aides and nurses are in short supply, and turnover can run 50 percent or higher. The PE play is to consolidate regional agencies, centralize back office, and leverage technology like scheduling algorithms and telehealth to reduce overhead and improve clinician retention. Luna: Right, so it's a classic roll-up: buy fragmented local operators, standardize processes, and hopefully sell to a larger strategic buyer or take public. Have there been any notable exits yet? Lucas: We've seen a few. In 2024, Webster Equity Partners sold one of its home health platforms to a large managed care organization for something north of two billion dollars. And several pe backed agencies have filed for IPOs, though the public markets have been choppy. The bigger trend now is that the largest strategic buyers — think UnitedHealth, Humana, CVS — are buying these platforms directly to control the entire care continuum. Luna: So the exit path is there. But given the labor shortages, how do these firms actually improve margins without cutting quality? Because Medicare has quality star ratings tied to reimbursement. Lucas: That's the challenge exactly. The firms that succeed focus on technology: better scheduling to reduce driving time between visits, remote patient monitoring to catch issues before a hospitalization, and even ai assisted documentation so nurses spend less time on paperwork. There's a firm called The Vistria Group that rolled up three regional agencies in the Southeast into a single platform, and they reported a 12-point improvement in patient satisfaction scores within two years. Luna: That's impressive. It suggests that consolidation done right can actually improve care. Lucas: If these conversations have moved your work forward in some small way — maybe helped you think about a sector differently or gave you a framework to evaluate a roll-up — a couple of dollars a month genuinely makes a difference. It's what keeps the show ad-free and independent. If that feels right, you can find us at buy me a coffee dot com slash fexingo. Luna: Yeah, it's a small gesture that goes a long way. Appreciate everyone who chips in. Lucas: So back to home health. The regulatory environment is another factor. In May 2026, the Centers for Medicare and Medicaid Services proposed a new rule that would tighten the requirements for agencies to qualify for Medicare payments, essentially raising the bar on quality reporting and staffing standards. Luna: That could be a double-edged sword for PE owners: higher barriers make it harder for small independent agencies to stay in business, which creates more acquisition targets, but it also means the buyers need to invest more upfront to bring those agencies into compliance. Lucas: Exactly. The sophisticated buyers are actually using that regulatory pressure as a tailwind. They acquire a bunch of small agencies that are mom and pop operations, install a compliance system, centralize billing, and within a year or two they have a platform that meets or exceeds the new standards. The smaller operators who can't afford the compliance burden sell out, which feeds the consolidation cycle. Luna: It sounds like the winners are the ones with operational expertise, not just financial engineering. Is that a shift from the earlier PE playbook? Lucas: I think it is. In the rush to buy up urgent care centers and physical therapy clinics a few years ago, some firms got burned because they didn't understand the local labor dynamics or the thicket of state regulations. Home health is even more regulated — every state has its own licensing requirements, and Medicare's conditions of participation are detailed. The firms that are doing well now are often hiring former healthcare executives to run their portfolio companies, not just investment bankers. Luna: So what's the endgame for a typical home health roll-up? Is it ultimately selling to a health insurer or a hospital system? Lucas: That's the most likely exit, yes. Insurers want to own the patient's full journey, and home health is a critical touchpoint. Hospitals also see it as a way to reduce readmissions, which cost them penalties under Medicare. There's also the possibility of a dividend recap — essentially borrowing against the acquired agency's cash flows to pay the PE firm a dividend — but that's riskier if interest rates stay elevated. I think we'll see more outright sales to strategics over the next two to three years. Luna: Given the aging population, this seems like a sector with a long tail. Do you think PE will eventually saturate the market, or will there always be room for new entrants? Lucas: Home health is still highly fragmented. The top ten agencies control maybe twenty percent of the market. There are thousands of independent operators. So there's room for consolidation to continue for another decade, especially as the regulatory and technology demands grow. But the prices have gotten more expensive — multiples have expanded from about six times EBITDA five years ago to nine or ten times now for high-quality platforms. So the returns won't be as spectacular as the early movers saw. Luna: So the smart money might be looking at adjacent segments like hospice or private-duty nursing, where consolidation is still in earlier stages. Lucas: Exactly. Hospice is especially interesting because the demographics are even more skewed toward the very old, and the reimbursement model is per diem, which can be very profitable if you control costs. I wouldn't be surprised if, a few episodes from now, we're talking about private equity buying up hospice agencies. Luna: Well, let's put that on the list. For now, home health gives us a clear picture of how PE is using demographics, regulation, and technology to reshape a critical part of healthcare delivery. Lucas: It's a good reminder that behind every roll-up, there's a real service being provided — or not, if the execution fails. The next few years will tell us which firms built real operating muscle and which ones just stacked debt on a fragile business model.